## **Core Concept**
The question tests knowledge of specific oncogenes and their activation mechanisms, particularly focusing on those involved in chromosomal translocations. Oncogenes are genes that have the potential to cause cancer. They can become activated (or "oncogenic") as a result of mutations or increased expression. Chromosomal translocations, which involve the exchange of genetic material between chromosomes, can lead to the activation of oncogenes by placing them under the control of different regulatory elements or by fusing them with other genes.

## **Why the Correct Answer is Right**
The correct answer involves the understanding that certain oncogenes are activated through translocation events. Specifically, the **BCR-ABL** fusion gene, resulting from a translocation between chromosomes 9 and 22 (t(9;22)), is a well-known example. This translocation creates the Philadelphia chromosome, characteristic of chronic myeloid leukemia (CML) and some cases of acute lymphoblastic leukemia (ALL). The BCR-ABL fusion protein has constitutive tyrosine kinase activity, leading to uncontrolled cell proliferation.

## **Why Each Wrong Option is Incorrect**
- **Option A:** While **MYC** is indeed an oncogene involved in various cancers, its activation is more commonly associated with mutations or increased expression rather than a specific translocation event as seen with BCR-ABL.
- **Option B:** **KRAS** is another important oncogene, frequently mutated in human cancers. However, KRAS activation typically occurs through point mutations rather than chromosomal translocations.
- **Option D:** **HER2** (also known as ERBB2) is involved in breast cancer and can be amplified or overexpressed but is not typically activated by a translocation event.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that the **BCR-ABL** fusion gene, resulting from the t(9;22) translocation, is a hallmark of CML and some ALL cases. This has significant therapeutic implications, as targeted therapies like tyrosine kinase inhibitors (e.g., imatinib) have revolutionized the treatment of these diseases.

## **Correct Answer:** . BCR-ABL